SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001564590-19-012254
Filing Date
2019-04-22
Accepted
2019-04-22 16:10:50
Documents
8
Effectiveness Date
2019-04-22

Document Format Files

Seq Description Document Type Size
1 DEFA14A aldx-defa14a_20190604.htm DEFA14A 80320
2 GRAPHIC gcbsovscnhlv000006.jpg GRAPHIC 1111
3 GRAPHIC gcbsovscnhlv000004.jpg GRAPHIC 1111
4 GRAPHIC gcbsovscnhlv000007.jpg GRAPHIC 1111
5 GRAPHIC gcbsovscnhlv000001.jpg GRAPHIC 1099
6 GRAPHIC gcbsovscnhlv000003.jpg GRAPHIC 1343
7 GRAPHIC gcbsovscnhlv000002.jpg GRAPHIC 1343
8 GRAPHIC gcbsovscnhlv000005.jpg GRAPHIC 1343
  Complete submission text file 0001564590-19-012254.txt   94300
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36332 | Film No.: 19759547
SIC: 2834 Pharmaceutical Preparations